Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
Laboratory Study of the Influence of Oral Cannabidiol on the Subjective, Reinforcing and Cardiovascular Effects of Smoked Marijuana
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40513
- University of Kentucky, Straus Behavioral Research Bldg., 515 Oldham Ct.
-
-
New York
-
New York, New York, United States, 10032
- Marijuana Outpatient Lab 1051 Riverside Dr. Unit #120
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Center for Drug and Alcohol Programs, Room 459 North, 67 President St.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults between the ages of 18 and 50.
- Current marijuana use: Minimum of four times per week, 0.5 joints per occasion during the preceding 4 weeks.
- Able to perform study procedures
- Women practicing an effective form of birth control
Exclusion Criteria:
- Female subjects who are currently pregnant or breastfeeding.
- Current, repeated illicit drug use other than marijuana
- Presence of significant medical illness
- History of heart disease
- Request for drug treatment
- Current parole or probation
- Recent history of significant violent behavior
- Major psychiatric disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Active marijuana (MJ) with 0 mg CBD
Active MJ cigarettes contain 5.30% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
|
Other: Active MJ with 200 mg CBD
Active MJ cigarettes contain 5.30% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
|
Other: Active MJ with 400 mg CBD
Active MJ cigarettes contain 5.30% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
|
Other: Active MJ with 800 mg CBD
Active MJ cigarettes contain 5.30% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
|
Other: Inactive MJ with 0 mg CBD
Inactive MJ cigarettes contain 0.01% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
|
Other: Inactive MJ with 200 mg CBD
Inactive MJ cigarettes contain 0.01% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
|
Other: Inactive MJ with 400 mg CBD
Inactive MJ cigarettes contain 0.01% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
|
Other: Inactive MJ with 800 mg CBD
Inactive MJ cigarettes contain 0.01% THC
|
Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order.
Cigarettes contained either 0.01 or 5.30% THC.
At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mood Scale - Subscale 'Feeling High'
Time Frame: two hours before and after marijuana cigarette smoking
|
Participants rated how much they felt having a "high" feeling from smoked marijuana using a visual analog scale 1-100 mm, 1 (Not at all) - 100 (extremely).
|
two hours before and after marijuana cigarette smoking
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Marijuana Rating Form - Like
Time Frame: 15 - 120 minutes after marijuana cigarette smoking
|
Participants rated how much they liked the effects of smoked marijuana using a visual analog scale 1-100 mm, 1=least, 100= most
|
15 - 120 minutes after marijuana cigarette smoking
|
|
Marijuana Rating Form - Strength
Time Frame: 15 - 120 minutes after marijuana cigarette smoking
|
Participants rated the strength effects of smoked marijuana using a visual analog scale 1-100 mm, 1=least, 100= most
|
15 - 120 minutes after marijuana cigarette smoking
|
|
Optional Additional Puffs of MJ Cigarette
Time Frame: 150 to 250 minutes after first marijuana cigarette was smoked earlier in the day
|
Participants were allowed to choose to take or reject additional puffs of the same type of MJ cigarette they smoked earlier in the day.
Counts of participants choosing to take additional puffs are reported.
|
150 to 250 minutes after first marijuana cigarette was smoked earlier in the day
|
|
Number of Optional Puffs of MJ Cigarette Taken
Time Frame: 150 to 160 minutes after first marijuana cigarette was smoked earlier in the day
|
Mean number of puffs taken by those participants who chose to take additional puffs.
|
150 to 160 minutes after first marijuana cigarette was smoked earlier in the day
|
|
Heart Rate
Time Frame: 120 minutes before and 150 minutes after marijuana cigarette smoking
|
Heart rate measured at 10 time points, 4 before and 6 after smoking cannabis.
|
120 minutes before and 150 minutes after marijuana cigarette smoking
|
|
Plasma Concentration of CBD
Time Frame: 6 hours
|
Plasma concentrations of cannabidiol were measured at six time points after oral administration of four 200 mg capsules of CBD.
|
6 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Margaret Haney, M.D., New York State Psychiatric Institute
- Study Director: Robert J Malcolm, M.D., Medical University of South Carolina
- Study Director: Sharon Walsh, Ph.D., University of Kentucky
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Study Number CBD-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.